AngioDynamics (NASDAQ:ANGO) Updates FY20 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.90 million.AngioDynamics also updated its FY 2020 guidance to $0.25-0.30 EPS.

Shares of NASDAQ ANGO traded up $0.56 during midday trading on Wednesday, hitting $21.06. The company’s stock had a trading volume of 510,100 shares, compared to its average volume of 218,894. The business’s 50 day moving average price is $19.52. The firm has a market capitalization of $757.80 million, a price-to-earnings ratio of 28.46 and a beta of 0.69. AngioDynamics has a 12-month low of $18.11 and a 12-month high of $25.48. The company has a current ratio of 2.68, a quick ratio of 1.70 and a debt-to-equity ratio of 0.23.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, hitting the consensus estimate of $0.25. The company had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. AngioDynamics’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the business posted $0.20 EPS. As a group, research analysts expect that AngioDynamics will post 0.83 EPS for the current year.

A number of analysts have commented on the company. ValuEngine cut Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. BidaskClub raised Zebra Technologies from a hold rating to a buy rating in a report on Saturday. TheStreet cut WCF Bancorp from a c rating to a d+ rating in a report on Thursday, April 18th. Finally, Zacks Investment Research raised Investar from a hold rating to a buy rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $21.50.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: What is the QQQ ETF?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.